Need ONE Response Per Each Discussion Total 3 Responses. Attached Are The Discussions And Rubric Please Follow Them. Posts Will Be A Minimum Of 100 Words, APA Format.One Reference Per Each Discussion
butterflyl
CASESTU51.docxCASE STUDY 2
Florida National University
Ariel Lopez
March 18, 2020
Introduction
H. Pylori is a bacteria that is found in the stomach. This disease is capable of causing other digestive issues such as stomach cancer as well as ulcers. The bacteria affect the protective tissue that is in the stomach. In addition, it causes changes to the duodenum and stomach. Some of the signs and symptoms include nausea, bloating, vomiting, lack of appetite, and dark or tar colored stool, (Pachathundikandi, et al., 2019). Research shows that up to twenty percent of a patient with this disease do not get cured after completing the first course of treatment. In this case, the patient was given clarithromycin for fourteen days, Cipro for two weeks and Omeprazole for two week
If the medication does not work, it is advisable to avoid using the same antibiotics when retreating the patient. Bismuth quadruple therapy is recommended for a patient who initially received clarithromycin, (Li, et al., 2017). When deciding on the salvage therapy, the patient antibiotic exposure, as well as the local antimicrobial resistance data, should be considered. Bismuth quadruple therapy or levofloxacin for two weeks is the most preferred salvage regimens. Other regimes include concomitant therapy for ten days to two weeks, rifabutin for ten days, and high dose dual therapy for two weeks. Clarithromycin is not preferred for salvage therapy.
Conclusion
Due to the decrease in the success rate of H. Pylori eradication therapy. Continuous infection is not uncommon after treatment. Fecal antigen testing, urea breath test, and biopsy-based test can be used to determine the treatment success. It is important to test the patient after four weeks, (Suzuki & Mori, 2018). After the completion of antibiotics and after therapy has been withheld for seven to fourteen days. It is essential to discuss the challenges and benefits of the therapy. Factors such as smoking and diabetes mellitus play an important role in treatment failure.
Reference
Li, T. H., Qin, Y., Sham, P. C., Lau, K. S., Chu, K. M., & Leung, W. K. (2017). Alterations in gastric microbiota after H. pylori eradication and in different histological stages of gastric carcinogenesis. Scientific reports, 7, 44935.
Pachathundikandi, S. K., Tegtmeyer, N., Arnold, I. C., Lind, J., Neddermann, M., Falkeis-Veits, C., ... & Sticht, H. (2019). T4SS-dependent TLR5 activation by Helicobacter pylori infection. Nature Communications, 10(1), 1-11.
Suzuki, H., & Mori, H. (2018). World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat. Journal of gastroenterology, 53(3), 354-361.
